Mediwatch is a small company destined to become a much bigger fish by the time this year is out. Mediwatch are already a market leader in urological medical diagnostics equipement and are currently exporting their products throughout the UK, Canada, Europe, India and Japan. That doesn't leave much of the globe left for them to capture - until you remember the good ol' US and China. These are the two massive markets which are destined to be added to MDW's export client portfolio by the end of 2005.

Website: www.mediwatch.com

The company is currently heavily undervalued. This is probably because Mediwatch's speciality is not a very glamourous business to be in as their equipment is used extensively to diagnose prostate cancer in men and other nasty urological conditions affecting both men and women. However, don't let that put you off investing in these guys. This is big business and is growing at an exponential rate as more and more people globally become health-aware as they get older. Mediwatch normally supply their products through to global markets via distribution agreements. They already have the best of distribution partners in the well known US medical distributor CR Bard who supply Canada and Europe and GE Medical who supply Japan. The UK business is handled by Mediwatch's own dedicated sales team. US FDA approval was gained for MDW's products at the start of last year, however a whole year of US legal wrangling meant that they were unable to seek a suitable partner for the crucial distribution agreement until the start of this year. This distribution agreement is expected by the board to have a "significant effect" on the share price so they are reluctant to give any clues as to when it will be signed, sealed and delivered. The general consensus is that this US distribution agreement will be announced in July/August. In China and Hong Kong, MDW have done things the other way round. They have set up distribution agreements with major Asian medical equipment distributors and have stock already out there waiting to sell into the markets - all they are waiting for is SDA approval (which is a "rubber stamp") from the Chinese authorities - this can take anything up to 12 months to come through and MDW applied during Autumn 2004 - so even more good news coming soon this year. Epidemiological data from British Association of Urology conference last year: On average 30-45% of all men between the age of 50 and 70 have at least one PSA test per year in the US / Italy / Australia. If that's not enough to convince you to invest a few hard earned coppers in MDW, they are also developing a PSA stick test product (PSAWatch) which is revolutionary and causing some excitement in medical circles. This product can also be adapted (at very low cost) for a whole spectrum of medical disciplines from Cardiology to Veterinary Practice! This product is likely to be released in the next few weeks. Philip Stimpson the CEO has said that this product is going to be their "gold mine" - I'm sure it will prove to be ours too.

more good news


Home Log Out Upgrade Our Services My Account Contact Help



Stockwatch Level 2 Portfolio Charts Shares Magazine Research Quote Indices Market Scan Company Zone Traders' Room
NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News Mobile Futures Forward Diary Investors' Room
Credit Cards Banking Directory Savings Personal Finance Insurance Loans Book Shop Mortgages Forex Games Room







Mediwatch PLC
09 November 2005

Mediwatch secures another major equipment order.

Mediwatch plc (AIM: MDW), the high-tech medical diagnostic equipment
manufacturer and supplier has received an order worth 1.05 million from Bard
Limited, one of the world's leading marketers of medical equipment. This
represents an increase of some 10% over the equivalent order for 2005 and
confirms the product's leading position in the market.

This is the latest and third annual phase of a five year agreement with Bard
under which Mediwatch will supply the British and European subsidiaries of the
giant US distribution company C.E.Bard (NYSE: BCR) with its range of portable
bladder scanners, marketed as the BARDSCAN.

Earlier this week, Mediwatch announced that it has also agreed a major world
wide deal with medical equipment giant Medtronic to distribute its ground
breaking MULTISCAN diagnostic device.

As well as linking Mediwatch to Medtronic's well-established, extensive, medical
equipment sales network - backed up by proven marketing campaigns - the
agreement will introduce the Multiscan to many new and important international
markets.

Said Mediwatch CEO Philip Stimpson: 'These contracts confirm that Mediwatch
equipment is now regarded as a sector leader by two of the largest and most
successful medical distribution companies in the world.

' The technology we provide is increasingly being recognised as some of the best
in the business.'

Mediwatch, based in Rugby, supplies advanced yet simple to use medical equipment
to screen for a variety of urological and prostate disorders.

With increasing life expectancy and an ageing population, prostate and
urological conditions are among the fastest growing health problems encountered
by doctors today.

The innovative BARDSCAN has rapidly gained a place as the industry standard for
portable, point of care bladder volume calculations by healthcare professionals.

Mediwatch is also developing a new, smaller and cheaper PSA test (PSAwatch) for
diagnosis and surveillance of prostate disease.



For more information, please contact Mediwatch CEO Philip Stimpson on
01788-547888. Or look at our website:
www.mediwatch.com

Not dead now robstuff!!

Hope you are right opt,lets get this one moving.

mmm..on re-read not a massive RNS as it just confirms part of an already agreed deal.....all be it now a bit larger...the best news seems to be EVO now not constantly on the offer.....lets see what tomrrow brings

It's just waiting like a coiled spring.Hopefully get some good press this week/w-end.Think friday will be interesting....

EVO now a buyer not a seller......added a few more this morning......will add again on confirmed break of 15p

The markets do work in strange ways,any ideas why the sp is DOWN so much,after the r n s we been waiting for?

Thx

Still have the Far East news to come out over the next month?
This could be bigger than the US.
Distribution partners all ready on board just waiting approval ( 12 months into process now).

http://www.advfn.com/cmn/fbb/thread.php3?id=5456944&from=3039

Also from the dark side,my view:

still trying to learn and understand charting,so it is always good to hear from fingers,whether it be good/bad news.
Mediwatch will start moving soon,we just have to wait for investors to notice this obviously little known company,to see what it has achieved and where it is going.

We could have done with a little bit more info on the exact deal that was struck with Medtronic but this will come with time and no doubt through MDT themselves.

Been a long wait I know,with expectations high after recent announcements and no massive rises,has caused a bit of a :-(( with investors,just be a bit more patient and things will be tickerty boo-imho

looks like we will ahve to wait until interims on the 20th Jan for any range break.

back to sleep until then i think

looking good today!

With all the possible news why wait for the interims.

14p+ by end of tomorrow..........well maybe :-)

should get some buying tomorrow with the Medica trade show in full swing,MDW and MDT both have stands there(obviously MDT's stand is a bit bigger!)

Still awaiting MDT's anouncement about the deal with MDW and when that happens it's classed as Global news! Just me thoughts!

well guys its saturday and i never check my emails, however one of my jukeboxes is appearing on the lottery show for the next 18 weeks so I have just been online to check a few things.

what did I find in my inbox??? my rhps (red hot penny shares tips) and some nice fellow called bullford has been to meet our ceo and as a result we have this little gem

Medical breakthrough! This cheap and portable test for prostate cancer could help 51 million men every year



Prostate cancer killed my dear old dad, and is responsible for about 10,000 deaths each year in this country. As I approach 50, I am just one of many who wonder whether it might now come after me.

In actual fact the majority of men will have prostate cancer by the time they reach the age of 90, even though it is rarely life threatening unless it spreads to other parts of the body.

But if spotted early enough it can be treated. As awareness grows, it is hardly surprising that more and more men want a check-up.

The soaring cost of men's health

Two million prostate assessments are made each year in the UK alone, and this is costing the health service plenty. The checks are mostly conducted in hospitals, and each one costs the NHS up to 400.

Is there any way of reducing the bill... whilst improving men's health?

Mediwatch is a small AIM-listed company that has come up with a method for testing for prostate cancer that could save the NHS a fortune - and put many minds at rest, too. It has invented a cheap test for Prostate Specific Antigens (PSA). My friends in the medical profession tell me that it could be on to a winner.

To check this out I went up to Rugby to meet 63-year old Chief Executive Philip Stimpson. We spent an interesting morning talking about things like 'significant bladder trabeculation' and an 'obstructed flow curve with terminal dribble'. These problems can prove as ugly as they sound. Philip then showed me some of the advanced, yet simple to use, medical equipment developed by his company. All of them screen for a variety of urological or prostate disorders. Such conditions are, thanks to the ageing population, amongst the fastest growing health problems encountered by doctors today. This is a boom market.

Two simple solutions

One of Mediwatch's products is the Portaflow, a urinal on wheels in effect. It measures the rate and volume of urine flow and instantly prints out the results. Another new tool is the Bioscan reader, a simple portable kit that tests for PSAs in the blood. High levels can indicate looming problems.

Millions of the over 50s in the Western world have at least one PSA test per year. At present each one must first visit their GP to make an appointment, then go to hospital for the test, and then wait anxiously at home for a fortnight for the results. The Mediwatch test is the world's first and only instant PSA test. It can be performed in a GP's office, rather than needing a trip to hospital, and could cut the direct cost to the NHS by more than half.

The PSA test is the first step, and is followed, if necessary, by a prostate biopsy. While two million tests are carried out in hospitals in the UK each year, the figures overseas are much greater. Fifteen million tests are conducted in the US, with another 34m in Europe, China and Japan combined. The savings offered by Mediwatch's PSA testing device are as attractive overseas as they are here in the UK.

All of the devices developed by Mediwatch are portable. And thanks to modern communications technology the test results can instantly be transmitted, via a wireless link, to the patient's records on the computer in the doctor's office. This is a hugely important breakthrough. It raises the prospect that tests could be made on a visit to a patient's home, rather than in hospital. This would be especially attractive in the US, of course, where patients may have to travel many miles to the nearest doctor's surgery.

Moving into the vast US market

Last month Mediwatch signed a highly significant marketing and distribution deal with giant US corporation Medtronic. The deal should mark a steep change in Mediwatch's growth.

Medtronic will have exclusive rights in the United States and elsewhere to sell a product developed by Mediwatch called Multiscan. The Multiscan provides portable real-time ultrasound imaging, with bladder and prostate volume and size calculations. When combined, via Bluetooth wireless connections, to a Portaflow machine and a Bioscan quantitative PSA reader, it can provide a complete one-stop urological assessment, providing comprehensive reports for the prostate and bladder. At present Mediwatch's products are distributed throughout the UK, France, Scandinavia and Benelux by medical equipment distributor CR Bard. GE Medical Systems distributes them in South East Asia, and MC Medical (a division of Mitsubishi) delivers them in Japan. Last month Bard placed an order worth 1.05m with Mediwatch, an increase of some 10% over the equivalent order last year.

No profits yet... plus big R&D spend

However, Mediwatch is yet to make a profit. It has also been spending heavily on research and development. Last year that swallowed up about 30% of the company's 1.8m turnover. But despite the absence of profits, shareholders who subscribed for new shares at a price of 6.5p in a placing last July have seen their shares rise. Encouraged by rising sales, confidence in the future is growing.

RHPS Verdict: Mediwatch is not making profits, and no financial forecasts are available. I understand a broker may soon be preparing some forecasts, but, in the meantime, the figures in the table below are my own tentative guesswork. The rising share price indicates a degree of faith in Mediwatch's future, and the PSA test kit seems highly promising. However, this investment is highly speculative at this stage. So I am putting the share on our Watch List.





Saturday 03 December 2005 07:22PM


Red Hot Penny Shares Issue # 85,


-------------------------------------------------------------------------------

last time he put something on his watch list it was at 2p and was only 6 months or so back, that company was stanleco they promptly rose to 30p before retracing from memory bullford changed his stance from watch to hold when they hit around 15p. this will get mdw on many more radars and we all know that minimal buying will cause the price to rise, and I strongly believe that is why over the last week the mms have been walking this down knowing that what they pick up now will be sold vastly higher.

time for a chinese and a nice bottle of red, hopefully we should see some action on monday so will be up early for level 2 updates.

Should give us a lift in the morning Smudge :-)

Looking good for 2006
:-)

Nice steady buying

MM's must be well short of stock.
+ we have all the news to break + results in Jan.

leedslad,why do you think the nn,s are short of stck as the sells have been much heavier over the last couple weeks than the buys which is why the sp has fallen from 14p?,good to see it moving again.